376P - Impact of pre-radiotherapy haemoglobin levels on treatment breaks in locally advanced head and neck squamous cell carcinoma getting concurrent chem...

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anticancer Agents
Head and Neck Cancers
Surgical Oncology
Presenter Rajesh Narayanasamy
Citation Annals of Oncology (2016) 27 (suppl_9): ix112-ix122. 10.1093/annonc/mdw587
Authors R.K. Narayanasamy1, S. Thyagarajan1, M. Sekhar2, B. Ramakrishnan3, K. Perumal4
  • 1Radiotherapy, Rai CBCC Cancer Center, 600095 - Chennai/IN
  • 2Oral Surgery, Saveetha Dental College, 600095 - Chennai/IN
  • 3Biostatistics, Apollo Speciality Hospital, 600006 - Chennai/IN
  • 4Radiation Oncology, Apollo Speciality Hospital, 600035 - Chennai/IN



Chemoradiation is standard of care for treating locally advanced head and neck squamous cell carcinoma (HNSCC). Unplanned interruption during treatment has the chance of inducing tumour repopulation. Treatment breaks occur due to various reasons like treatment related side effects, poor nutrition and compliance. We prospectively analysed the role pre-RT haemoglobin and its influence on treatment breaks.


120 HNSCC (T3-T4a, N1-N2c) patients undergoing chemoradiation were prospectively evaluated for influence of Pre-RT haemoglobin on mucositis. Sub-sites included were oral cavity, ororphaynyx, hypopharnyx & laynyx. All patients received weekly inj.cisplatin 40 mg/m2) along with radiation to a total dose of 66Gy to PTV. All patients were evaluated weekly by clinical examination for grade of dermatitis, dysphagia, mucositis and hemogram.


Our population was characterized by a mean age of 55±10.7 years (range: 27-69), 85 were males and 35 females with a performance status of ECOG 1-2. All patients were in locally advanced disease stage III –IV. The mean pre-RT haemoglobin was calculated (using ROC) as 10.3 g/dl. Among 120 patients 58 had treatment breaks ≥five days (of which 6 were >10.3g/dl and 52 were 10.3g/dl and only 2 were 


Lower pre-RT haemoglobin level of 

Clinical trial indentification

Legal entity responsible for the study





All authors have declared no conflicts of interest.